TMPRSS2:ERG gene fusion, which is reported to occur in between 20–80% of prostate cancer [81,82], leads to changes promoting EMT, as demonstrated in an in vitro prostate cancer model consisting of immortalised prostate epithelial cells in culture [83]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.